Digital Look

Welcome to Digital Look++,
you are not logged in

Valirx (VAL)

Pharma and Biotech

3.35p

	£ (Millions)	£ (Millions)
Cash Flow Statement	31-Dec-10	31-Dec-09

Net Cash Flow From Operating Activities	(0.49)	(0.92)
ROI, Servicing of Finance
Assocs/JV Dividends Received	_bn/a	_bn/a
Interests & Other Dividends Received	n/a	n/a
Interest Paid	_bn/a	_bn/a
Minorities & Non-Equity Divs Paid	_bn/a	_bn/a
	n/a	n/a

Taxation Paid	_bn/a	_bn/a

Gross Cash Flow	_bn/a	_bn/a

Capital Expd & Financial Inv
Interests & Other Dividends Received	(0.01)	n/a
Disposal of Property, Plant & Equipment	n/a	n/a
Disposal of Investments	n/a	n/a
Purchase of Property, Plant & Equipment	(0.01)	n/a
Purchase of Investments	n/a	n/a
Net Purchase of Intangible Assets	n/a	(0.07)
Other Investing Cash Flow	(0.06)	n/a
	(0.08)	(0.07)
Financing Activities
Dividends Paid	n/a	n/a
Repayments of Borrowings	n/a	n/a
Borrowings	n/a	n/a
Other Financing Cash Flow	0.70	0.97
	0.70	0.97
Net Increase/Decrease In Cash	0.14	(0.03)

Key Financials	31-Dec-10	31-Dec-09

Shares in Issue - Year End	491.30	153.15

Financial Data
Cash Incr/Decr per Share	0.045p	(0.022p)
Operating Cash Flow per Share	(0.16p)	(0.73p)
Gross Cash Flow per Share	_bn/a	_bn/a

Market Data
Price/Operating Cash Flow	(23,031.9)	(29,559.5)

* GAAP

a. Operating activities before tax

b. Not disclosed under IFRS

c. Not previously included in financing activities

d. Based on operating cash flow before tax

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: Forecast figures based on normalised accounts.